Pharmacological evaluation of aprindine (AC 1802) a new antiarrhythmic agent.
D000284:Administration, Oral; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001341:Autonomic Nervous System / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D005021:Ethylamines / Q000494:pharmacology / Q000627:therapeutic use; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D007192:Indenes / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D007928:Lethal Dose 50; D051379:Mice; D011437:Propylamines / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D012119:Respiration / Q000187:drug effects; D014693:Ventricular Fibrillation / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D005021:Ethylamines; D007192:Indenes; D011437:Propylamines